Ionis Pharmaceuticals (IONS) – Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Ionis Pharmaceuticals (NASDAQ: IONS):

• 7/16/2026 – Ionis Pharmaceuticals had its “peer perform” rating reaffirmed by Wolfe Research.
• 7/13/2026 – Ionis Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $100.00 to $85.00. They now have an “outperform” rating on the stock.
• 7/10/2026 – Ionis Pharmaceuticals had its price target lowered by Citigroup Inc. from $115.00 to $100.00. They now have a “buy” rating on the stock.
• 7/10/2026 – Ionis Pharmaceuticals had its price target lowered by Barclays PLC from $115.00 to $90.00. They now have an “overweight” rating on the stock.
• 7/10/2026 – Ionis Pharmaceuticals had its price target lowered by HC Wainwright from $130.00 to $125.00. They now have a “buy” rating on the stock.
• 7/10/2026 – Ionis Pharmaceuticals had its price target lowered by Morgan Stanley from $130.00 to $110.00. They now have an “overweight” rating on the stock.
• 7/10/2026 – Ionis Pharmaceuticals had its price target lowered by Canaccord Genuity Group Inc. from $110.00 to $95.00. They now have a “buy” rating on the stock.
• 7/9/2026 – Ionis Pharmaceuticals had its price target lowered by Jefferies Financial Group Inc. from $113.00 to $90.00. They now have a “buy” rating on the stock.
• 7/9/2026 – Ionis Pharmaceuticals had its price target lowered by Jefferies Financial Group Inc. from $113.00 to $90.00. They now have a “buy” rating on the stock.
• 7/9/2026 – Ionis Pharmaceuticals was given a new $87.00 price target by Raymond James Financial, Inc..
• 7/9/2026 – Ionis Pharmaceuticals had its price target lowered by Needham & Company LLC from $105.00 to $86.00. They now have a “buy” rating on the stock.
• 6/25/2026 – Ionis Pharmaceuticals had its price target raised by HC Wainwright from $125.00 to $130.00. They now have a “buy” rating on the stock.
• 6/25/2026 – Ionis Pharmaceuticals had its price target raised by Leerink Partners from $122.00 to $129.00. They now have an “outperform” rating on the stock.
• 6/24/2026 – Ionis Pharmaceuticals had its price target raised by The Goldman Sachs Group, Inc. from $74.00 to $75.00. They now have a “neutral” rating on the stock.
• 6/17/2026 – Ionis Pharmaceuticals had its price target raised by Leerink Partners from $114.00 to $122.00. They now have an “outperform” rating on the stock.
• 6/15/2026 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by TD Cowen. They now have a $108.00 price target on the stock.
• 5/27/2026 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $125.00 price target on the stock.
• 5/18/2026 – Ionis Pharmaceuticals is now covered by Citigroup Inc.. They set a “buy” rating and a $115.00 price target on the stock.
• 5/18/2026 – Ionis Pharmaceuticals was upgraded by Citigroup Inc. from “buy” to “strong-buy”.

Insider Buying and Selling

In related news, EVP C Frank Bennett sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $85.46, for a total value of $1,281,900.00. Following the completion of the sale, the executive vice president owned 75,018 shares in the company, valued at $6,411,038.28. The trade was a 16.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Eric Swayze sold 10,602 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $79.18, for a total value of $839,466.36. Following the completion of the sale, the executive vice president directly owned 21,759 shares of the company’s stock, valued at approximately $1,722,877.62. This represents a 32.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 233,163 shares of company stock valued at $18,316,551 in the last three months. 1.81% of the stock is owned by corporate insiders.

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.